^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PL001

    i
    Other names: PL001, CD19-targeted chimeric antigen receptor T-cell
    Associations

    News

    Trials
    Company:
    Pell Bio-Med Techno
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    4ms
    Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=49, Recruiting, Pell Bio-Med Technology Co., Ltd. | Trial completion date: Sep 2024 --> Mar 2026 | Trial primary completion date: Aug 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    cyclophosphamide • PL001
    almost2years
    Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T) for Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=49, Recruiting, Pell Bio-Med Technology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • PL001
    2years
    Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T) for Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=49, Not yet recruiting, Pell Bio-Med Technology Co., Ltd.
    New P1/2 trial • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • PL001